CogState has announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests
Acusphere, Inc. announced today the issuance of U.S. Patent No. 7,160,557 B2, entitled "Matrices Formed of Polymer and Hydrophobic Compounds for Use in Drug Delivery." The patent covers the s
Nanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, has announced that they would appeal the decision of the European Patent Office (EPO) to uphold t
Heska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liqu
Nano Chemical Systems announced today that it has filed a US Patent application on a breakthrough new material that exhibits light (luminescent) in the absence of heat. This Nano-enhanced
Ranbaxy Laboratories Limited announced that the Federal Court of Canada has handed down a favorable decision in the company's case against Pfizer by finding invalid Pfizer's Canadian atorvastatin pate
Thai Public Health Minister Mongkol Songkhla plans to break patents on an antiretroviral drug and a drug for heart disease by issuing compulsory licenses to produce lower-cost versions,
Access Pharmaceuticals, Inc. announced today that it was issued U.S. Patent No. 7,166,733 by the U.S. Patent and Trademark Office. This patent, entitled "O,O'-Amidomalonato and N,O-Amidom
Archus Orthopedics, Inc. has announced that the European Patent Office has confirmed the validity of its patent number EP-B-1223872 following an Opposition that concluded with oral proceedings on Ja
This patent covers adenovirus AAV (Ad-AAV) hybrid vectors encoding the receptor for very low density lipoprotein (VLDL). These vectors are potentially very efficient and useful in the production of AAV vectors to treat hyperlipidemia. The Ad-AAV hybrid vector covered by this patent could also be used as a standalone therapeutic. The patent was issued to University of Pennsylvania and is exclusively licensed to Targeted Genetics.
"Today's patent is an important addition to our preclinical hyperlipidemia program, which is designed to evaluate a number of therapeutic gene candidates delivered by AAV vectors, including the receptor for VLDL, an important receptor for regulating lipid levels including cholesterol in blood," said Barrie J. Carter, Ph.D., chief scientific officer of Targeted Genetics.
"AAV vectors have become one of the most promising systems for gene delivery, due to AAV's many characteristics that make it broadly applicable to in vivo prevention and treatment of a number of diseases," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "Our intellectual property covers a broad range of AAV assets, and places Targeted Genetics in a leadership position in the field. We believe that our AAV technology and manufacturing expertise sets us apart and will continue to be major assets in our future product development and partnering activities."
AAV vectors are derived from a naturally occurring virus that has never been associated with any disease. AAV vectors can efficiently deliver genetic information to numerous cell types and can be engineered to carry a variety of DNA sequences, including genes, RNAi, antisense, and nucleic acids to encode peptides and monoclonal antibodies. AAV vectors are highly stable and persist in cells for extended periods of time, which allows for long term gene expression.
Hyperlipidemia, which is thought to play a role in cardiovascular disease, is linked to the elevation of lipids, or fats, such as cholesterol, in the bloodstream. Approximately four million people in the United States have a genetic predisposition to some form of hyperlipidemia, such as familial hypercholesterolemia, familial combined hyperlipidemia and polygenic hypercholesterolemia. Approximately 10% of these patients have severe forms of the disease and do not respond to standard drug therapy, such as statins. If untreated, disease progression can lead to morbidity and death from heart attack or stroke.
http://www.targetedgenetics.com/